Mounting evidence supports the use of blood-based neurodegenerative biomarkers as a low-cost, minimally invasive tool for studying Alzheimer's disease and other dementias, but existing data largely come from clinical samples or high-income settings. Despite emphasis in the literature on the importance of understanding the utility of neurodegenerative biomarkers in diverse populations, published analyses are limited.
Objective
To assess the utility of neurodegenerative biomarkers in India by quantifying associations between biomarkers and cognitive outcomes in a nationally representative cohort study.
Methods
We quantified associations between five neurodegenerative blood biomarkers (amyloid-β 42/40 (Aβ42/40), total tau, phosphorylated Tau181 (pTau-181), glial fibrillary acidic protein (GFAP), neurofilament light (NfL)) and cross-sectional and longitudinal cognitive outcomes using nationally-representative data from the Longitudinal Aging Study in India–Diagnostic Assessment of Dementia (N = 4096).
Results
We observed associations between biomarkers and cross-sectional cognitive functioning (Aβ42/40, GFAP, and NfL) and longitudinal cognitive change (pTau-181 and NfL). NfL had the strongest associations; each SD increase in log NfL was associated with 0.007 (95% CI 0.000 to 0.014) SD unit/year worse cognitive decline, equivalent to about 35% of the mean longitudinal decline in the sample. We saw little evidence of effect modification by demographic variables or APOE ε4 status.
Conclusions
Neurodegenerative biomarkers were associated with cross-sectional and longitudinal outcomes as well as mortality, though there was variation in outcome-specific findings across biomarkers. Findings generally support the use of neurodegenerative biomarkers in India. Future research in India should leverage these biomarkers to address a range of research topics, including heterogeneity in dementia phenotypes.
NicholsESteinmetzJDVollsetSE, et al.Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health2022; 7: e105–e125.
2.
WimoAAliGCGuerchetM, et al.World Alzheimer Report 2015: The global impact of dementia: An analysis of prevalence, incidence, cost and trends, https://www.alzint.org/resource/world-alzheimer-report-2015/ (21 September 2015, accessed 10 April 2023).
3.
JutkowitzEKaneRLGauglerJE, et al.Societal and family lifetime cost of dementia: implications for policy. J Am Geriatr Soc2017; 65: 2169–2175.
4.
DigmaLAWinerJRGreiciusMD. Substantial doubt remains about the efficacy of anti-amyloid antibodies. J Alzheimers Dis2024; 97: 567–572.
5.
WalshSMerrickRMilneR, et al.Considering challenges for the new Alzheimer’s drugs: clinical, population, and health system perspectives. Alzheimers Dement2024; 20: 6639–6646.
6.
NicholsEMerrickRHaySI, et al.The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia. Lancet Healthy Longev2023; 4: e115–e125.
7.
RobinsonJLXieSXBaerDR, et al.Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. Brain J Neurol2023; 146: 2557–2569.
8.
LiYSchindlerSEBollingerJG, et al.Validation of plasma amyloid-β 42/40 for detecting Alzheimer disease amyloid plaques. Neurology2022; 98: e688–e699.
9.
MielkeMMHagenCEXuJ, et al.Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement2018; 14: 989–997.
10.
AbdelhakAFoschiMAbu-RumeilehS, et al.Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol2022; 18: 158–172.
11.
AshtonNJJanelidzeSAl KhleifatA, et al.A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun2021; 12: 3400.
12.
TosunDDemirZVeitchDP, et al.Contribution of Alzheimer’s biomarkers and risk factors to cognitive impairment and decline across the Alzheimer’s disease continuum. Alzheimers Dement2022; 18: 1370–1382.
13.
XiaoZWuXWuW, et al.Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease. Alzheimers Res Ther2021; 13: 123.
14.
MeyerPFAshtonNJKarikariTK, et al.Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults. Ann Neurol2022; 91: 548–560.
15.
Hayes-LarsonEAckleySFTurneyIC, et al.Considerations for use of blood-based biomarkers in epidemiologic dementia research. Am J Epidemiol2024; 193: 527–535.
16.
Adkins-JacksonPBGeorgeKMBesserLM, et al.The structural and social determinants of Alzheimer’s disease related dementias. Alzheimers Dement2023; 19: 3171–3185.
17.
KobayashiLCJonesRNBriceñoEM, et al.Cross-national comparisons of later-life cognitive function using data from the harmonized cognitive assessment protocol (HCAP): considerations and recommended best practices. Alzheimers Dement2024; 20: 2273–2281.
18.
TorresJMGlymourMM. Future directions for the HRS harmonized cognitive assessment protocol. Forum Health Econ Policy2022; 25: 7–27.
19.
United Nations Department of Economic and Social Affiars, Population Division. World population prospects 2022: summary of results. New York, NY: United Nations, Department of Economic and Social Affairs, Population Division, 2022.
20.
YadavSArokiasamyP. Understanding epidemiological transition in India. Glob Health Action2014; 7: 23248.
21.
PrinceM. Dementia in developing countries. A consensus statement from the 10/66 dementia research group. Int J Geriatr Psychiatry2000; 15: 14–20.
22.
CousinsKAQPhillipsJSDasSR, et al.Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease. Alzheimers Dement2024; 20: 3889–3905.
23.
NallapuBTPetersenKKLiptonRB, et al.Plasma biomarkers as predictors of progression to dementia in individuals with mild cognitive impairment. J Alzheimer’s Dis2024; 98: 231–246.
24.
GuYHonigLSKangMS, et al.Risk of Alzheimer’s disease is associated with longitudinal changes in plasma biomarkers in the multi-ethnic Washington heights–Hamilton heights–inwood Columbia aging project (WHICAP) cohort. Alzheimers Dement2024; 20: 1988–1999.
25.
de WolfFGhanbariMLicherS, et al.Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. Brain J Neurol2020; 143: 1220–1232.
26.
SullivanKJBlackshearCSiminoJ, et al.Association of midlife plasma amyloid-β levels with cognitive impairment in late life. Neurology2021; 97: e1123–e1131.
27.
ZhangYFerreiraPCLJacobsenE, et al.Association of plasma biomarkers of Alzheimer’s disease and related disorders with cognition and cognitive decline: the MYHAT population-based study. Alzheimers Dement J Alzheimers Assoc2024; 20: 4199–4211.
28.
KhobragadePNicholsEMeijerE, et al.Performance of the informant questionnaire on cognitive decline for the elderly (IQCODE) in a nationally representative study in India: the LASI-DAD study. Int Psychogeriatr2022; 36: 177–187.
29.
NicholsEDeySKhobragadeP, et al. Socioeconomic and clinical predictors of all-cause mortality among older adults in India from 2017–2024 in a nationally representative, longitudinal study: The Importance of Cognitive Health and Dementia [Preprint]. 26 November 2024. DOI: https://doi.org/10.2139/ssrn.5032672.
30.
LeeJPetrosyanSKhobragadeP, et al.Deep phenotyping and genomic data from a nationally representative study on dementia in India. Sci Data2023; 10: 45.
31.
LangaKMRyanLHMcCammonRJ, et al.The health and retirement study harmonized cognitive assessment protocol project: study design and methods. Neuroepidemiology2020; 54: 64–74.
32.
GrossALNicholsERenteriaMA, et al. Risk and protective factors against cognitive decline in older adults from a nationally representative sample in India: Results from the LASI-DAD. medRxiv 2025. DOI: https://doi.org/10.1101/2025.07.07.25331027v1[Preprint]. Posted July 10, 2025.
33.
GrossALKhobragadePYMeijerE, et al. Measurement and structure of cognition in the longitudinal aging study in India-diagnostic assessment of dementia. J Am Geriatr Soc2020; 68(Suppl 3): S11–S19.
34.
InkerLAEneanyaNDCoreshJ, et al.New creatinine- and cystatin C–based equations to estimate GFR without race. N Engl J Med2021; 385: 1737–1749.
35.
HaneuseSVanderWeeleTJArterburnD. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. JAMA2019; 321: 602–603.
36.
RustandDvan NiekerkJKrainskiET, et al.Fast and flexible inference for joint models of multivariate longitudinal and survival data using integrated nested Laplace approximations. Biostat Oxf Engl2024; 25: 429–448.
37.
LumleyT. Analysis of complex survey samples. J Stat Softw2004; 9: 1–19.
38.
TherneauT. A package for survival analysis in S. R Package Version2015; 2: 2014.
39.
SimrénJLeuzyAKarikariTK, et al.The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement2021; 17: 1145–1156.
40.
KivisäkkPCarlyleBCSweeneyT, et al.Plasma biomarkers for diagnosis of Alzheimer’s disease and prediction of cognitive decline in individuals with mild cognitive impairment. Front Neurol2023; 14: 1069411.
41.
GrassetLBouteloupVCacciamaniF, et al.Associations between blood-based biomarkers and cognitive and functional trajectories among participants of the MEMENTO cohort. Neurology2024; 102: e209307.
42.
TsikniaAAEdlandSDSundermannEE, et al.Sex differences in plasma p-tau181 associations with Alzheimer’s disease biomarkers, cognitive decline, and clinical progression. Mol Psychiatry2022; 27: 4314–4322.
43.
Zabala-FindlayAPennyLKLofthouseRA, et al. Utility of blood-based tau biomarkers for mild cognitive impairment and Alzheimer’s disease: systematic review and meta-analysis. Cells2023; 12: 1184.
44.
ToledoJBVandersticheleHFigurskiM, et al.Factors affecting aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol2011; 122: 401–413.
45.
ChatterjeePPedriniSDoeckeJD, et al.Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer’s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement2023; 19: 1117–1134.
46.
YaffeKWestonAGraff-RadfordNR, et al.Association of plasma β-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA2011; 305: 261–266.
47.
DarkHEAnYDugganMR, et al.Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline. Alzheimers Res Ther2024; 16: 94.
48.
WangXBakulskiKMKarvonen-GutierrezCA, et al.Blood-based biomarkers for Alzheimer’s disease and cognitive function from mid- to late life. Alzheimers Dement2023; 20: 1807–1814.
49.
GuoDZhangXZhanC, et al.Sex differences in the association between obesity and cognitive impairment in a low-income elderly population in rural China: a population-based cross-sectional study. Front Neurol2021; 12: 669174.
50.
WojdałaALBellomoGGaetaniL, et al.Trajectories of CSF and plasma biomarkers across Alzheimer’s disease continuum: disease staging by NF-L, p-tau181, and GFAP. Neurobiol Dis2023; 189: 106356.
51.
SternY. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol2012; 11: 1006–1012.
52.
AschenbrennerAJLiYHensonRL, et al.Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol2022; 9: 1739–1751.
53.
PlancheVBouteloupVPellegrinI, et al.Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort. Neurology2023; 100: e473–e484.
54.
Cortes-CanteliMIadecolaC. Alzheimer’s disease and vascular aging. J Am Coll Cardiol2020; 75: 942–951.
55.
RabinJSNicholsELa JoieR, et al.Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline. Brain J Neurol2022; 145: 2823–2833.
56.
SchneiderJAWilsonRSBieniasJL, et al.Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology2004; 62: 1148–1155.
57.
SchneiderJABoylePAArvanitakisZ, et al.Subcortical infarcts, Alzheimer’s disease pathology, and memory function in older persons. Ann Neurol2007; 62: 59–66.
58.
HosokiSHansraGKJayasenaT, et al.Molecular biomarkers for vascular cognitive impairment and dementia. Nat Rev Neurol2023; 19: 737–753.
59.
PrabhakaranDJeemonPRoyA. Cardiovascular diseases in India. Circulation2016; 133: 1605–1620.
60.
Davis-PlourdeKLMayedaERLodiS, et al.Joint models for estimating determinants of cognitive decline in the presence of survival bias. Epidemiol Camb Mass2022; 33: 362–371.
61.
Pichet BinetteAJanelidzeSCullenN, et al.Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement2023; 19: 1403–1414.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
